Limited-Time Offer [Flat 15% Discount] Dismiss

Updated Data Matrix Available
Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global CINV Drugs Market $4.3 Billion by 2031

February 3, 2025 by iHealthcareAnalyst, Inc.

The global market for chemotherapy-induced nausea and vomiting (CINV) drugs estimated to reach $4.3 billion by 2031, expanding at a CAGR of 8.2% over the forecast period, driven by recent advances in medications, and increase in the number of highly effective agents to treat chemotherapy-induced nausea and vomiting condition.

- Other market driving factors include increasing number of patients undergoing chemotherapy treatments and newly approved drugs with minimum side-effects

Privacy - Terms

HELSINN EXHIBIT 2006
Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
IPR2025-00946

Limited-Time Offer [Flat 15% Discount] Dismiss

Chemotherapy-induced nausea and vomiting (CINV) classified as acute, delayed or anticipatory based on the timing and type of chemotherapy drugs involved. Incidence and timing of CINV vary according to patient factors and chemotherapeutic agents. Incidence has been reported in as high as 70%–80% of patients.

The most commonly referred to published guidelines from the American Society of Clinical Oncology (ASCO), the Oncology Nursing Society (ONS) and the National Comprehensive Cancer Network (NCCN) clearly delineate the prevention and treatment of CINV.

Limited-Time Offer [Flat 15% Discount] Dismiss

prophylactic antiemetics for chemotherapy regimens with emetogenic potential less than 10%.

- The three categories of drugs with the highest therapeutic index for the management of CINV include:
  - Type three 5-hydroxytryptamine (5-HT3) receptor antagonists,
  - Neurokinin-1 receptor (NK1R) antagonists,
  - Glucocorticoids (especially dexamethasone).
  - 5-HT3 serotonin receptor antagonists include dolasetron, granisetron, ondansetron and palonosetron.
  - Neurokinin 1 (NK1) receptor antagonists are used for delayed CINV include aprepitant (oral formulation) and fosaprepitant (IV formulation).
  - Corticosteroids include dexamethasone and methylprednisone, whereas other miscellaneous agents include metoclopramide, compazine, cannabinoids, benzodiazepines, and antihistamines.
    - These agents are used alone and in specific combinations, depending on the emetogenicity of the specific chemotherapy regimen being administered and its tendency to produce not only acute but also delayed emesis.

The global chemotherapy-induced nausea and vomiting (CINV) drugs market report provides market size ($million 2021 to 2031), market share, growth trends and forecast (CAGR%, 2025 to 2031).

The global market for chemotherapy-induced nausea and vomiting treatment segmented by product [marketed drugs [5-HT3-receptor

Limited-Time Offer [Flat 15% Discount] Dismiss

generic (ondansetron), Kytril generic (granisetron), neurokinin1-receptor antagonists – Emend (aprepitant) / Proemend (fosaprepitant meglumine) / Cinvanti (aprepitant), netupitant-palonosetron fixed-dose combination IV (NEPA FDC) – Akynzeo (Netupitant-palonosetron FDC)], pipeline drugs [5-HT3-receptor antagonists – SUSTOL (Granisetron injection – extended release), neurokinin1-receptor antagonists – Varubi / Varuby (rolapitant)], and geography.

- Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patients' quality of life and on their ability to tolerate and comply with therapy.
  - Despite advances in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), these side effects remain among the most distressing for patients.
    - The use of emerging antiemetic medications has reduced the incidence of vomiting substantially, but evaluations show that approximately 30% to 60% of patients still experience either acute or delayed nausea after chemotherapy.
- Based on the marketed products category, the Aloxi (palonosetron) drug segment accounted for the largest share of the total CINV market.
  - Currently, four 5-HT_3 receptor antagonists are available in the United States -ondansetron, granisetron, dolasetron, and palonosetron.
    - Since their introduction, 5-HT_3 receptor antagonists have become part of the cornerstone for CINV

Limited-Time Offer [Flat 15% Discount] Dismiss

effect profile.

- Aloxi is one of the most commonly prescribed drugs to treat CINV. Palonosetron, the newest agent, was approved in 2003.
  - It is is available in oral as well as IV dosage forms, indicated in adults for the prevention of acute and delayed nausea and vomiting associated with moderate to high emetogenic chemotherapy.
    - Evidence suggests that the 5-HT_3-receptor antagonists administered in combination with corticosteroids afford the best protection from symptoms of acute emesis and, by extrapolation, the most effective prevention of delayed emesis.

The global CINV treatment market research report is further divided by geography North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

- Geographically, the North America region represented the largest market share of the total CINV drugs in terms of revenue, followed by the Europe region, primarily due to the increasing incidence of various types of cancer and anticipated product approval during the next few years.
  - On the other hand, the emerging markets in the Asia Pacific region expected to exhibit huge opportunities characterized by increasing market penetration by generic manufacturers, during the forecast period.

Limited-Time Offer [Flat 15% Discount] Dismiss

(market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in the global market for chemotherapy-induced nausea and vomiting treatment and included in this report are GSK plc (Tesaro, Inc. / GlaxoSmithKline), Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Ono Pharmaceutical Co., Ltd.

- **Product**
  - Marketed Drugs
    - 5-HT3-receptor Antagonists (5-HT3RAs)
      - Aloxi (palonosetron)
      - Anzemet (dolasetron)
      - Zofran Generic (ondansetron)
      - Kytril Generic (granisetron)
    - Neurokinin1-receptor Antagonists (NK1RAs)
      - Emend (aprepitant) / Proemend (fosaprepitant meglumine) / Cinvanti (aprepitant)
    - Netupitant-Palonosetron Fixed-Dose Combination IV (NEPA FDC)
      - Akynzeo (netupitant/palonosetron FDC)
  - Pipeline Drugs
    - 5-HT3-receptor Antagonists (5-HT3RAs)
      - SUSTOL (Granisetron Injection – extended release)
    - Neurokinin1-receptor Antagonists (NK1RAs)
      - Varubi / Varuby (rolapitant)

Limited-Time Offer [Flat 15% Discount] Dismiss

  - North America (U.S., Canada)
  - Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
  - Asia Pacific (Japan, China, India, Rest of APAC)
  - Latin America (Brazil, Mexico, Rest of LA)
  - Rest of the World
- **Company Profiles**
  - GSK plc (Tesaro, Inc. / GlaxoSmithKline)
  - Helsinn Holding S.A. (Helsinn Healthcare/ Helsinn Group)
  - Heron Therapeutics, Inc.
  - Merck & Co., Inc.
  - Ono Pharmaceutical Co., Ltd.

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/chemotherapy-induced-nausea-and-vomiting-drugs-market/

Related publications:

- Chemotherapy-Induced Nausea and Vomiting Drugs Market by Major Drugs (Marketed Drugs, and Pipeline Drugs) and Forecast 2024-2031
- Post-operative Nausea and Vomiting (PONV) Market by Treatment (Pharmacological Treatment – Dopamine Antagonists, NK-1 Receptor Antagonists, Serotonin Antagonists, Steroids, and Non-pharmacological Treatment); by Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) and Forecast 2024-2031
- Global mHealth Services Market $315 Billion by 2031
- Global Anticoagulant Drugs Market $32.7 Billion by 2029

Limited-Time Offer [Flat 15% Discount] Dismiss

2029

Press Releases

Global Video Telemedicine Market $3.4 Billion by 2031

Global Airway Clearance Devices Market $870 Million by 2031

Request Table of Contents/Sample Analysis

Full Name*

Company Email*

Phone Number* [Please add country code]

Subject*

Global Chemotherapy-ind

Message*

Limited-Time Offer [Flat 15% Discount] Dismiss

Send

Market Data Matrix

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Recent Publications

Global Ambulatory Surgical and Emergency Center Services Market $125 Billion by 2031

Limited-Time Offer [Flat 15% Discount] Dismiss

Global Emphysema Treatment Devices Market $2.9 Billion by 2031

Global Chronic Low Back Pain Devices Market $17.5 Billion by 2031

Global Metabolic Bone Diseases Devices Market $7.5 Billion by 2031

Global Tumor Microwave Ablation Market $282 Million by 2031

Global Epilepsy Treatment Devices Market $7.4 Billion by 2031

Global Surgical Robots Market $135 Billion by 2031

Global Uterine Fibroids Embolization Devices Market $3.5 Billion by 2031

Global Contrast Media Formulations Market $11.2 Billion by 2031

Global Multi-Cancer Early Detection Assays Market $3.5 Billion by 2031

Global Minimal Residual Disease Diagnostics Market $5.1 Billion by 2031

Global Atrial Fibrillation Therapy Devices Market $19.5 Billion by 2031

Global Bone Cancer Regeneration and Repair Devices Market $3.5 Billion by 2031

Revenue Forecasting Techniques for New Pharmaceutical Drugs

Limited-Time Offer [Flat 15% Discount] Dismiss

Receive latest published reports, industry trends and future market outlook.

Full Name*

Company Email*

Phone Number* [Please add country code]

Subscribe

Resource Links

- About Us
- Clinical Trials
- Drugs@FDA
- Orange Book
- Premarket Approval
- Premarket Notification
- Publications

Terms and Conditions

Limited-Time Offer [Flat 15% Discount] Dismiss

- Careers
- Terms of Use
- How to Order
- Return Policy
- Privacy Policy
- Disclaimer Policy

Secure Online Payment

Search

Search

Contact Address

US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
Phone: +1 (314) 315-4764
India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
Phone: +91 (20) 25898524
Email: sales@ihealthcareanalyst.com

© 2025 iHealthcareAnalyst, Inc. | All Rights Reserved.